MetaCap

ABVC BioPharma (ABVC) vs SCYNEXIS (SCYX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

SCYNEXIS (SCYX) has outperformed ABVC BioPharma (ABVC) over the past year, losing 56.3% versus a loss of 67.8%. Over five years, SCYX leads with a -96.0% price change compared with -97.3% for ABVC. SCYNEXIS is the larger company by market cap ($23.7 million vs $23.4 million), about 1.0 times the size.

SCYNEXIS converts more of its revenue into profit, with a net margin of -41.8% versus -2671.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABVC-67.80%SCYX-56.25%
+70%-5%-80%
Nov 21, 20251 yearNov 20, 2026
ABVC-97.37%SCYX-95.83%
+20%-42%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABVC versus SCYX key metrics
MetricABVCSCYX
Share price$0.8663$2.38
Market cap$23.37M$23.69M
1-day change-1.56%-8.64%
YTD return-59.33%-52.93%
1-year return-67.80%-56.25%
5-year return-97.29%-96.00%
EPS (TTM)$-0.20$-0.23
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$296.00K$20.60M
Revenue growth (YoY)-41.91%+449.95%
Net income (latest FY)$-7.91M$-8.61M
Operating margin-2415.97%-78.03%
Net margin-2671.81%-41.79%
52-week high$2.87$9.12
52-week low$0.707$2.30
Distance from 52-week high-69.82%-73.90%
Analyst consensus—strong_buy
Avg. price target upside—+1426.47%
Average volume81.92K225.27K
Shares outstanding26.98M9.95M
Employees1618
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SCYX has outperformed ABVC by 11.5 percentage points over the past year.
  • SCYNEXIS is more profitable, keeping -41.8 cents of every revenue dollar as net income versus -2671.8 cents for ABVC BioPharma.
  • SCYNEXIS grew revenue faster in its latest fiscal year (+449.95% vs -41.91%).

About ABVC BioPharma

ABVC stock →

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients.

Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees

About SCYNEXIS

SCYX stock →

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence.

Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees

ABVC vs SCYX FAQ

Which is bigger, ABVC BioPharma or SCYNEXIS?

SCYNEXIS (SCYX) is larger, with a market capitalization of $23.69M compared with $23.37M for ABVC BioPharma (ABVC).

Which stock has performed better over the past year, ABVC or SCYX?

SCYX returned -56.25% over the past 12 months, compared with -67.80% for ABVC (price return, excluding dividends). Past performance does not predict future results.

Are ABVC BioPharma and SCYNEXIS in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons